Evolving antimicrobial chemotherapy for Staphylococcus aureus infections: Our backs to the wall

Staphylococcus aureus is responsible for many nosocomial and community-acqu ired infections. Its evolving resistance to traditional antimicrobial chemo therapy and emerging prevalence outside of the healthcare environment are s erious concerns. This review of the changing epidemiology of methicillin-re sistant S, aureus, the emergence of vancomycin (glycopeptide)-resistant iso lates, and the mechanisms of resistance to beta -lactams and glycopeptides provides an update for clinicians regarding effective strategies for treatm ent mechanisms of resistance to beta -lactams and glycopeptides provides an update for clinicians regarding effective strategies for treatment mechani sms of resistance to beta -lactams and glycopeptides provides an update for clinicians regarding effective strategies for treatment.